Mitigating the cryoprecipitate shortage by using apheresis plasma as a manufacturing source

Transfusion. 2023 Jun;63(6):1255-1256. doi: 10.1111/trf.17335.
No abstract available

Publication types

  • Letter

MeSH terms

  • Blood Component Removal*
  • Factor VIII / therapeutic use
  • Fibrinogen / therapeutic use
  • Humans
  • Plasma

Substances

  • Factor VIII
  • Fibrinogen